These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 27960575)

  • 1. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.
    Roland CL; Setnik B; Brown DA
    Postgrad Med; 2017 Jan; 129(1):12-21. PubMed ID: 27960575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
    Hale ME; Moe D; Bond M; Gasior M; Malamut R
    Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
    Lourenço LM; Matthews M; Jamison RN
    Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting labels of abuse-deterrent opioid analgesics.
    Webster LR
    J Opioid Manag; 2017; 13(6):415-423. PubMed ID: 29308588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
    Schaeffer T
    J Med Toxicol; 2012 Dec; 8(4):400-7. PubMed ID: 23073726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamper-resistant opioid formulations in the treatment of acute pain.
    Passik SD
    Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the development of prescription opioid abuse-deterrent formulations.
    Katz NP; Adams EH; Chilcoat H; Colucci RD; Comer SD; Goliber P; Grudzinskas C; Jasinski D; Lande SD; Passik SD; Schnoll SH; Sellers E; Travers D; Weiss R
    Clin J Pain; 2007 Oct; 23(8):648-60. PubMed ID: 17885342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety.
    Cheatle MD
    Pain Med; 2015 Oct; 16 Suppl 1():S3-8. PubMed ID: 26360931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community.
    By K; McAninch JK; Keeton SL; Secora A; Kornegay CJ; Hwang CS; Ly T; Levenson MS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):473-478. PubMed ID: 28833803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.